This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com featured highlights General Motors, Cemex, Centene, Qifu Technology and Deutsche Bank
by Zacks Equity Research
General Motors, Cemex, Centene, Qifu Technology and Deutsche Bank have been highlighted in this Screen of The Week article.
Elevance (ELV) Q4 Earnings Beat on Premium Growth, Dividend Hiked
by Zacks Equity Research
Elevance Health (ELV) expects 2024 premium revenues to remain in line with the 2023 level.
5 Promising Price-to-Book Value Stocks to Buy Now
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. General Motors Company (GM), Cemex (CX), Centene (CNC), Qifu Technology (QFIN) and Deutsche Bank Aktiengesellschaft (DB) are some such stocks.
Focus on These 4 Low P/CF Stocks to Maximize Returns in 2024
by Sumit Singh
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. PVH Corp. (PVH), Centene (CNC), General Motors (GM) and Graphic Packaging (GPK) boast a low P/CF ratio.
Centene (CNC) Chosen to Serve New Hampshire's Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members.
Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.
Molina Healthcare, Inc (MOH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Molina (MOH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Molina Healthcare (MOH) Up 26.9% in 6 Months: What Lies Ahead?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to keep growing on the back of increases in investment income and Medicare premiums.
Why You Should Retain Elevance (ELV) Stock in Your Portfolio
by Zacks Equity Research
Elevance's (ELV) Carelon unit is expected to benefit from improving performance in the Behavioral Health business and post-acute care services.
Centene (CNC) Sells Circle Health to Boost Managed Care Business
by Zacks Equity Research
Centene (CNC) concludes the divestiture of Circle Health to expand its core Managed Care business. Additionally, its plan members will enjoy continued access to Kroger's pharmacy network in 2024.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UnitedHealth (UNH) Stock Declines 3.4% on High Medical Costs
by Zacks Equity Research
As more seniors resume elective procedures, claims rise in UnitedHealth's (UNH) Medicare Advantage business.
UnitedHealth Group (UNH) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 3.01% and 2.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Can UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q4 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results are expected to benefit from an increase in UnitedHealthcare's Medicare & Retirement revenues as well as the number of people it served.
Brookdale (BKD) Sees Growth in December 2023 Occupancy Volumes
by Zacks Equity Research
Brookdale (BKD) witnesses a continuous streak of 26 months of year-over-year increases in the weighted average occupancy level.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Should Value Investors Buy Centene (CNC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Can UnitedHealth (UNH) Q4 Earnings Navigate Through High Costs?
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results are likely to reflect growth in domestic commercial customers and premium levels.
Why Centene (CNC) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Centene (CNC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Buy These 5 Price-to-Book Value Stocks for Gains in 2024
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. General Motors Company (GM), Park Hotels & Resorts (PK), Qifu Technology (QFIN), Centene (CNC) and Deutsche Bank Aktiengesellschaft (DB) are some such stocks.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Here's Why You Should Retain Centene (CNC) Stock For Now
by Zacks Equity Research
Centene (CNC) remains well-poised for growth on the back of overall membership growth, acquisitions, business streamlining efforts and a growing cash balance.
Reasons to Retain HCA Healthcare (HCA) Stock in Your Portfolio
by Zacks Equity Research
HCA Healthcare's (HCA) improving top line, acquisition initiatives and a robust growth outlook poise the company well for growth.
Why You Should Retain Cigna (CI) Stock in Your Portfolio
by Zacks Equity Research
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, growing medical membership and a positive 2023 outlook poise it well for growth.